Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC